Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1
| Autor: | Molly M. Brickler, David M. Margolis, Michael E. Kelly, Donald Basel, Matthew J. Ehrhardt, Gabriela Gheorghe |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Myeloid Hematopoietic cell Microarray business.industry Hematology Early Therapy medicine.disease medicine.anatomical_structure Scalp Neuroblastoma Internal medicine Pediatrics Perinatology and Child Health Immunology medicine Myeloid sarcoma Childhood Neuroblastoma business |
| Zdroj: | Pediatric Blood & Cancer. 61:1701-1703 |
| ISSN: | 1545-5009 |
| DOI: | 10.1002/pbc.25040 |
| Popis: | Survival following childhood neuroblastoma is improving with low rates of secondary myeloid neoplasms. We describe a 13-month-old male with intermediate risk neuroblastoma who developed an isolated scalp therapy-related myeloid sarcoma (t-MS). Developmental delays and two distinct malignancies prompted constitutional evaluation. Chromosomal microarray identified a 7.3 Mb deletion of 9q22.32 to 9q31.1. He remains in remission 11 months following hematopoietic cell transplant. Unusual presentations of rare diseases necessitate a multidisciplinary approach and adaptation of standardized protocols to accommodate increased risks imposed by genetic variants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text